BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11103785)

  • 1. Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
    Maiti S; Alam R; Amos CI; Huff V
    Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
    Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
    Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
    Ruteshouser EC; Robinson SM; Huff V
    Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.
    Amini Nik S; Hohenstein P; Jadidizadeh A; Van Dam K; Bastidas A; Berry RL; Patek CE; Van der Schueren B; Cassiman JJ; Tejpar S
    Int J Cancer; 2005 Mar; 114(2):202-8. PubMed ID: 15540161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
    Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
    J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutional and somatic mutations in the WT1 gene in Wilms' tumor patients.
    Nordenskjöld A; Friedman E; Sandstedt B; Söderhäll S; Anvret M
    Int J Cancer; 1995 Nov; 63(4):516-22. PubMed ID: 7591260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
    Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
    Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
    Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
    Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors.
    Eccles MR; Yun K; Reeve AE; Fidler AE
    Am J Pathol; 1995 Jan; 146(1):40-5. PubMed ID: 7856737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
    Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
    Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAX 8 regulates human WT1 transcription through a novel DNA binding site.
    Fraizer GC; Shimamura R; Zhang X; Saunders GF
    J Biol Chem; 1997 Dec; 272(49):30678-87. PubMed ID: 9388203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
    Roberts DJ; Haber D; Sklar J; Crum CP
    Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database.
    Jeanpierre C; Denamur E; Henry I; Cabanis MO; Luce S; Cécille A; Elion J; Peuchmaur M; Loirat C; Niaudet P; Gubler MC; Junien C
    Am J Hum Genet; 1998 Apr; 62(4):824-33. PubMed ID: 9529364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
    Werner H; Roberts CT; Rauscher FJ; LeRoith D
    J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.